# Golimumab in Steroid-dependent Ulcerative Colitis: Induction and Maintenance of Clinical and Endoscopic Remission

> **NCT02412085** · PHASE4 · UNKNOWN · sponsor: **Istituto Clinico Humanitas** · enrollment: 100 (estimated)

## Conditions studied

- Colitis, Ulcerative

## Interventions

- **DRUG:** Golimumab

## Key facts

- **NCT ID:** NCT02412085
- **Lead sponsor:** Istituto Clinico Humanitas
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-03
- **Primary completion:** 2016-12
- **Final completion:** 2017-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2015-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02412085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02412085, "Golimumab in Steroid-dependent Ulcerative Colitis: Induction and Maintenance of Clinical and Endoscopic Remission". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02412085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*